Presentation is loading. Please wait.

Presentation is loading. Please wait.

Are we ready to implant LVAD’s in the less sick? Ileana L. Piña, MD, MPH Professor of Medicine and Epi/Pop Health Albert Einstein College of Medicine Associate.

Published byTracy Fuge Modified over 9 years ago

Similar presentations

Presentation on theme: "Are we ready to implant LVAD’s in the less sick? Ileana L. Piña, MD, MPH Professor of Medicine and Epi/Pop Health Albert Einstein College of Medicine Associate."— Presentation transcript:

1 Are we ready to implant LVAD’s in the less sick? Ileana L. Piña, MD, MPH Professor of Medicine and Epi/Pop Health Albert Einstein College of Medicine Associate Chief for Academic Affairs, Montefiore-Einstein Medical Center Consultant, FDA, CDRH, ODE

2

3 INTERMACS

4 Do we have equipoise? Smaller pumps, less intrusive Less invasive surgery Better survival with continuous flow pumps Improves HRQoL Known poor HRQoL in most NYHA Class III-IV Poor functional capacity We have been able to identify the Profiles and we have seen the difference in survival Drop in stroke rate? Gender differences Drop in infection rates

5 Do we have equipoise? Pumps are smaller  Surgery less invasive Continuous flow pumps—better survival  Pumps more durable Improvements in HRQoL

6 Figure 4 Comparisons for mechanical circulatory support patients with complete data on the EQ-5D according to Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) profiles: (A) visual analog scale; (B) mobility, any problems; (C)... Kathleen L. Grady, David Naftel, Lynne Stevenson, Mary Amanda Dew, Gerdi Weidner, Francis D. Pagani, James K... The Journal of Heart and Lung Transplantation, Volume 33, Issue 4, 2014, 412 - 421

7 Improvements in Functional Capacity Rogers J et al. JACC Vol. 55, No. 17, 2010

8 Improvements in line infection

9 Do we have equipoise? Profiles are truly descriptive and discriminatory Barge-Caballero E et al. Circ Heart Fail. 2013;6:763-772

10 Figure 4 Actuarial survival post-LVAD. Andrew J. Boyle, Deborah D. Ascheim, Mark J. Russo, Robert L. Kormos, Ranjit John, Yoshifumi Naka, Annetine... Clinical outcomes for continuous-flow left ventricular assist device patients stratified by pre-operative INTERMACS classification The Journal of Heart and Lung Transplantation, Volume 30, Issue 4, 2011, 402 - 407 Grp 1= Profile 1 Grp 2= Profile 2,3, Grp 3= Profile 4-7

11 Who are we implanting MCS? We are already implanting on the less sick

12 BUT Who are the patients? Age? When to intervene? NYHA Imprecise Nature and the “eye of the beholder”

13 A depiction of the clinical course of heart failure with associated types and intensities of available therapies. Allen L et al. Circulation 2012;125:1928-1952 Copyright © American Heart Association, Inc. All rights reserved.

14 All-Cause Mortality (NYHA Class II-III) HR 0.93 (95% CI 0.84, 1.02, P=0.13) HR 0.96 (95% CI: 0.79, 1.17), P = 0.70 0.18 Excellent medical/device therapy

15 Teuteberg JJ. J Am Coll Cardiol 2012;60:44–51)

16 P.C. Patel, G.C. Stewart, M.M. Kittleson, J.A. Cowger, C.B. Patel, M.M. Mountis, F.L. Johnson, J.E. Rame... 161 Patients with INTERMACS 4-7 Heart Failure Have Reduced Quality of Life The Journal of Heart and Lung Transplantation, Volume 31, Issue 4, Supplement, 2012, S62 - S63

17 Figure 2 Physical function/activities of daily living dimensions on the EQ-5D according to Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) profiles: (A) mobility problems; (B) unusual activities problems; and (C) self-care pr... Kathleen L. Grady, David Naftel, Lynne Stevenson, Mary Amanda Dew, Gerdi Weidner, Francis D. Pagani, James K... The Journal of Heart and Lung Transplantation, Volume 33, Issue 4, 2014, 412 - 421

18 Adult Primary Continuous Flow LVAD/BiVADs, n=6732 By Age Groups Months post implant Event: Death (censored at transplant and recovery) % Survival Grp 1: < 50 yrs, n= 1758 Deaths=293 INTERMACS: June 2006 – December 2012: CMS Report Grp 2: 50–64 yrs, n= 3054 Deaths=648 Grp 3: 65-69 yrs, n= 1030 Deaths= 275 Overall p <.0001 18 Grp 4: 70+ yrs, n= 889 Deaths= 268 Figure 3 INTERMACS 4/21/2013

19 Figure 21 Freedom from adverse events listed in Figure 19, stratified by Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) level. Error bars indicate±1 standard error. BIVAD, biventr... James K. Kirklin, David C. Naftel, Robert L. Kormos, Lynne W. Stevenson, Francis D. Pagani, Marissa A. Miller... Fifth INTERMACS annual report: Risk factor analysis from more than 6,000 mechanical circulatory support patients The Journal of Heart and Lung Transplantation, Volume 32, Issue 2, 2013, 141 - 156 http://dx.doi.org/10.1016/j.healun.2012.12.004

20 Figure 1 Time of cumulative hospital participation and patients entered into the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) database.... Kirklin et al. The Journal of Heart and Lung Transplantation, Volume 32, Issue 2, 2013, 141 - 156 Boyle AJ et al. JACC, Volume 63, Issue 9, 2014, 880 - 888 Figure 2 Impact of Age and Sex on Post-Discharge Bleeding, Hemorrhagic Stroke, Ischemic Stroke, and Pump Thrombosis Event rates for men are shown in gray, and rates for women are shown in black. Unacceptable risks for the less sick?

21

22 THANK YOU!

23

24 Preoperative INTERMACS Profiles Determine Postoperative Outcomes in Critically Ill Patients Undergoing Emergency Heart TransplantationClinical Perspective by Eduardo Barge-Caballero, Javier Segovia-Cubero, Luis Almenar-Bonet, Francisco Gonzalez-Vilchez, Adolfo Villa-Arranz, Juan Delgado-Jimenez, Ernesto Lage-Galle, Felix Perez-Villa, Jose L. Lambert-Rodríguez, Nicolas Manito-Lorite, Jose M. Arizon- Del Prado, Vicens Brossa-Loidi, Domingo Pascual-Figal, Luis De la Fuente-Galan, Marisa Sanz-Julve, Javier Muñiz-Garcia, and Marisa Crespo-Leiro Circ Heart Fail Volume 6(4):763-772 July 16, 2013 Copyright © American Heart Association, Inc. All rights reserved.

25 Causes of death pertaining to preoperative Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) profiles. Barge-Caballero E et al. Circ Heart Fail. 2013;6:763-772 Copyright © American Heart Association, Inc. All rights reserved.

26 Distribution of patients during the study period. Barge-Caballero E et al. Circ Heart Fail. 2013;6:763-772 Copyright © American Heart Association, Inc. All rights reserved.

27 Figure 1 EQ-5D visual analog scale (VAS) results according to according to Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) profiles. The range bars indicate the standard error. Kathleen L. Grady, David Naftel, Lynne Stevenson, Mary Amanda Dew, Gerdi Weidner, Francis D. Pagani, James K... The Journal of Heart and Lung Transplantation, Volume 33, Issue 4, 2014, 412 - 421

28 INTERMACS profile 1 --12 (5) NA 2-- 104 (42) 3-- 71 (29) 4--7 60 (24) Jorde UP et al. (J Am Coll Cardiol 2014;63:1751–7)

29 In-hospital postoperative outcomes after emergency heart transplantation. Barge-Caballero E et al. Circ Heart Fail. 2013;6:763-772 Copyright © American Heart Association, Inc. All rights reserved.

30 Long-term survival after heart transplantation. Barge-Caballero E et al. Circ Heart Fail. 2013;6:763-772 Copyright © American Heart Association, Inc. All rights reserved.

Download ppt "Are we ready to implant LVAD’s in the less sick? Ileana L. Piña, MD, MPH Professor of Medicine and Epi/Pop Health Albert Einstein College of Medicine Associate."

Similar presentations

VALUE BASED CARE: The Role of INTERMACS INTERMACS 8 TH Annual Meeting James B, Young, M.D. Study Chair – INTERMACS May 5 th, 2014.

VALUE BASED CARE: The Role of INTERMACS INTERMACS 8 TH Annual Meeting James B, Young, M.D. Study Chair – INTERMACS May 5 th, 2014.
Can Comparative Effectiveness Study Tell Us What Is The Best Therapy For Class IV Heart Failure? Beta blockers or LVADs?

Can Comparative Effectiveness Study Tell Us What Is The Best Therapy For Class IV Heart Failure? Beta blockers or LVADs?
Hemolysis in Patients Supported with Durable, Long-Term Left Ventricular Assist Device Therapy Jason N. Katz, MD,MHS; Brian C. Jensen, MD; Patricia P.

Hemolysis in Patients Supported with Durable, Long-Term Left Ventricular Assist Device Therapy Jason N. Katz, MD,MHS; Brian C. Jensen, MD; Patricia P.
Sixth Annual Meeting March 12, 2012 8:00am to 4:00pm Crowne Plaza National Airport Arlington, VA INTERMACS Annual Meeting March 2012.

Sixth Annual Meeting March 12, :00am to 4:00pm Crowne Plaza National Airport Arlington, VA INTERMACS Annual Meeting March 2012.
Donor Utilization: Making Use of a Precious Resource in Cardiac Transplant Jason W. Smith, MD Assistant Professor of Surgery The University of Washington.

Donor Utilization: Making Use of a Precious Resource in Cardiac Transplant Jason W. Smith, MD Assistant Professor of Surgery The University of Washington.
Equipoise Does Not Exist for REVIVE IT Andrew Boyle, MD Heart and Vascular Center Director, Florida Chairman of Cardiology Medical Director of Heart Failure,

Equipoise Does Not Exist for REVIVE IT Andrew Boyle, MD Heart and Vascular Center Director, Florida Chairman of Cardiology Medical Director of Heart Failure,
Predicting Major Outcomes after MCSD Implant 1 Risk Factors for Death, Transplant, and Recovery James Kirklin, MD David Naftel, PhD.

Predicting Major Outcomes after MCSD Implant 1 Risk Factors for Death, Transplant, and Recovery James Kirklin, MD David Naftel, PhD.
Advances In LVAD Patient Management

Advances In LVAD Patient Management
What have we learned? What is next? Panel B: Functional Capacity, Quality of Life and Outcomes H.Functional Capacity I.Neurocognitive Assessment J.Quality.

What have we learned? What is next? Panel B: Functional Capacity, Quality of Life and Outcomes H.Functional Capacity I.Neurocognitive Assessment J.Quality.
Keith Aaronson, Mark Slaughter, Edwin McGee, William Cotts, Michael Acker, Mariell Jessup, Igor Gregoric, Pranav Loyalka, Valluvan Jeevanandam, Allen Anderson,

Keith Aaronson, Mark Slaughter, Edwin McGee, William Cotts, Michael Acker, Mariell Jessup, Igor Gregoric, Pranav Loyalka, Valluvan Jeevanandam, Allen Anderson,
Predicting Patients at Risk for Poor Global Outcomes after DT- MCS Therapy Suzanne V. Arnold, MD, MHA Saint Luke’s Mid America Heart Institute/UMKC May.

Predicting Patients at Risk for Poor Global Outcomes after DT- MCS Therapy Suzanne V. Arnold, MD, MHA Saint Luke’s Mid America Heart Institute/UMKC May.
Contemporary Outcomes With the HeartMate II® LVAS

Contemporary Outcomes With the HeartMate II® LVAS
Presentations: Quantifying the impact of adverse events on HRQOL early after implant Patient selection and estimation of prognosis using health status.

Presentations: Quantifying the impact of adverse events on HRQOL early after implant Patient selection and estimation of prognosis using health status.
Predicting Major Outcomes after MCSD Implant 1 Risk Factors for Death, Transplant, and Recovery James Kirklin, MD David Naftel, PhD.

Predicting Major Outcomes after MCSD Implant 1 Risk Factors for Death, Transplant, and Recovery James Kirklin, MD David Naftel, PhD.
Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients Assessment.

Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients Assessment.
Author Disclosures Differences in Implantation-Related Adverse Events Between Men and Women Receiving ICD Therapy for Primary Prevention Differences in.

Author Disclosures Differences in Implantation-Related Adverse Events Between Men and Women Receiving ICD Therapy for Primary Prevention Differences in.
HeartWare HVAD: Risk Factors for Adverse Outcomes Mark S. Slaughter, MD Professor and Chair Department Cardiovascular and Thoracic Surgery University of.

HeartWare HVAD: Risk Factors for Adverse Outcomes Mark S. Slaughter, MD Professor and Chair Department Cardiovascular and Thoracic Surgery University of.
MCS in Special Populations: The Use of Mechanical Support in Adults with Congenital Heart Disease 9 th Annual Meeting May 15, 2015 Christina VanderPluym,MD.

MCS in Special Populations: The Use of Mechanical Support in Adults with Congenital Heart Disease 9 th Annual Meeting May 15, 2015 Christina VanderPluym,MD.
Survival following VAD complications: implications for transplant priority. Todd Dardas, MD, MS May 16, 2015.

Survival following VAD complications: implications for transplant priority. Todd Dardas, MD, MS May 16, 2015.
Development of a novel predictive model for mortality post continuous flow LVAD implant using Bayesian Networks (BN) N. A. Loghmanpour 1, M. K. Kanwar.

Development of a novel predictive model for mortality post continuous flow LVAD implant using Bayesian Networks (BN) N. A. Loghmanpour 1, M. K. Kanwar.

Similar presentations

Ads by Google